MedTrace Logo

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

NCT02576847 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 307

Last updated 2022-07-19

Study results available
· View outcomes & findings →

Summary

This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.

Conditions

  • Rosacea

Interventions

DRUG

Omiganan

Topical gel

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-07-14
Completion
2018-02-08

Countries

  • United States
  • Australia
  • Canada
  • France
  • Netherlands
  • New Zealand
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02576847 on ClinicalTrials.gov